AU2007329464A1 - Thrombopoietin mimetics - Google Patents

Thrombopoietin mimetics Download PDF

Info

Publication number
AU2007329464A1
AU2007329464A1 AU2007329464A AU2007329464A AU2007329464A1 AU 2007329464 A1 AU2007329464 A1 AU 2007329464A1 AU 2007329464 A AU2007329464 A AU 2007329464A AU 2007329464 A AU2007329464 A AU 2007329464A AU 2007329464 A1 AU2007329464 A1 AU 2007329464A1
Authority
AU
Australia
Prior art keywords
compound
hydroxy
alkyl
substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007329464A
Other languages
English (en)
Inventor
Juha Punnonen
Jeffrey R. Spencer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STATegics Inc
Original Assignee
STATegics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STATegics Inc filed Critical STATegics Inc
Publication of AU2007329464A1 publication Critical patent/AU2007329464A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007329464A 2006-12-01 2007-11-30 Thrombopoietin mimetics Abandoned AU2007329464A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86196306P 2006-12-01 2006-12-01
US60/861,963 2006-12-01
PCT/US2007/086186 WO2008070583A2 (en) 2006-12-01 2007-11-30 Thrombopoietin mimetics

Publications (1)

Publication Number Publication Date
AU2007329464A1 true AU2007329464A1 (en) 2008-06-12

Family

ID=39493014

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007329464A Abandoned AU2007329464A1 (en) 2006-12-01 2007-11-30 Thrombopoietin mimetics

Country Status (6)

Country Link
US (2) US7786159B2 (enExample)
EP (1) EP2086551A4 (enExample)
JP (1) JP2010511631A (enExample)
AU (1) AU2007329464A1 (enExample)
CA (1) CA2670345A1 (enExample)
WO (1) WO2008070583A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP2010511631A (ja) * 2006-12-01 2010-04-15 ステイテジックス・インコーポレイテッド トロンボポエチン擬態物
US8476249B2 (en) 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
EP2427053A4 (en) * 2009-05-07 2012-12-05 Glaxosmithkline Llc METHOD FOR TREATING THROMBOCYTOPENIA
CN101921232A (zh) * 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
WO2012121958A2 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
EP2755955A4 (en) * 2011-09-13 2015-08-19 Glenmark Generics Ltd METHOD FOR PRODUCING SUBSTITUTED 3'-HYDRAZIN BIPHENYL-3-CARBOXYLIC ACID COMPOUNDS
US9492430B2 (en) * 2011-11-14 2016-11-15 Ligand Pharmaceuticals, Incorporated Methods and compositions associated with the granulocyte colony-stimulating factor receptor
JP6150374B2 (ja) * 2012-11-15 2017-06-21 国立大学法人弘前大学 放射線被ばく治療剤及び放射線被ばく治療方法
WO2014150252A1 (en) 2013-03-15 2014-09-25 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
CN104257928A (zh) * 2014-10-20 2015-01-07 王艳萍 一种治疗软组织损伤疼痛综合症的中药制剂
JP7481252B2 (ja) 2017-07-26 2024-05-10 ヤンセン ファーマシューティカ エヌ．ベー． 標的放射線治療誘発性血管完全性を保護する方法
MA54820A (fr) * 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
WO2024249284A2 (en) * 2023-05-26 2024-12-05 Ipsen Pharma S.A.S. Bax activators and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3141772A (en) * 1963-08-09 1964-07-21 Polaroid Corp Photographic products, processes and compositions employing azo dye developers
BE621310A (enExample) * 1961-08-10
DE1182432B (de) * 1962-04-26 1964-11-26 Basf Ag Verfahren zur Herstellung von thermoplastischen farbigen makromolekularen Stoffen
US3666746A (en) * 1969-06-25 1972-05-30 Gaf Corp Pyrrolidonylphenyl azo dyestuffs
US5132189A (en) * 1989-09-07 1992-07-21 Fuji Electric Co., Ltd. Photoconductor for electrophotography
JPH04128767A (ja) * 1990-09-19 1992-04-30 Fuji Electric Co Ltd 電子写真用感光体
KR100423881B1 (ko) * 1999-07-29 2004-03-22 미쯔이카가쿠 가부시기가이샤 황색계 화합물을 이용한 잉크젯기록용 수계 잉크
AU770564B2 (en) * 1999-09-10 2004-02-26 Smithkline Beecham Corporation Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US7414040B2 (en) 2002-06-06 2008-08-19 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
DE602005024599D1 (de) * 2004-10-25 2010-12-16 Ligand Pharm Inc Verbindungen modulierende thrombopoietinaktivität und verfahren
US7226575B2 (en) * 2004-11-30 2007-06-05 Chevron U.S.A. Inc. Boron-containing molecular sieve CHA
CA2630234A1 (en) * 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
JP2010511631A (ja) 2006-12-01 2010-04-15 ステイテジックス・インコーポレイテッド トロンボポエチン擬態物

Also Published As

Publication number Publication date
WO2008070583A3 (en) 2008-08-14
US7786159B2 (en) 2010-08-31
EP2086551A2 (en) 2009-08-12
US8143287B2 (en) 2012-03-27
US20100323965A1 (en) 2010-12-23
EP2086551A4 (en) 2011-06-08
JP2010511631A (ja) 2010-04-15
US20080139621A1 (en) 2008-06-12
WO2008070583A2 (en) 2008-06-12
CA2670345A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
US8143287B2 (en) Thrombopoietin mimetics
US6348480B1 (en) Pharmaceutical compound comprising a pyrazole derivative and methods of using the same for the treatment of calcium release-activated calcium channel associated diseases
CA2849169C (en) Pyrazole carboxamides as janus kinase inhibitors
DE69736642T2 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
CA2958490C (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives
KR101464060B1 (ko) 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
CA3180819A1 (en) Substituted aminothiazoles as dgkzeta inhibitors for immune activation
EA005205B1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛЫ КАК ИНГИБИТОРЫ р38 КИНАЗЫ
AU2006209712B2 (en) IGF-1R inhibitor
JP2010505957A (ja) 糖尿病に対して使用されるｎ−アリールピラゾール化合物
CA2816769A1 (en) Substituted heteroaromatic carboxamide and urea derivatives as vanilloid receptor ligands
CZ89798A3 (cs) Použití substituovaných pyrazoylbenzensulfonamidů ve veterinární praxi
HUE031408T2 (en) Pharmaceutical preparation
NZ209279A (en) 3-(piperidinyl)- and 3-(pyrrolidinyl)-1h-indazole derivatives and pharmaceutical compositions
AU2014234907B2 (en) Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors
JP6154804B2 (ja) アミドピリジン誘導体およびその用途
RS60099B1 (sr) Jedinjenja i kompozicije sa nokdaun efektom ili aktivnošću inhibicije hranjenja krvlju kod štetnih insekata
AU2004218260A1 (en) N-aryl heteroaromatic products, compositions containing same and use thereof
JPH05507281A (ja) ４−（１，２−ベンゾイソキサゾリル）ピペリジン抗精神病薬
US5877175A (en) Pharmaceutical compositions
AU2010333829A1 (en) CRTH2 modulators
JPWO2006112313A1 (ja) インダゾール誘導体を有効成分として含む網膜神経細胞保護剤
SA517390161B1 (ar) مشتقات إندول
CN113980001A (zh) 吡唑醇-哒嗪酮类耦联化合物、其药物组合物及其在药物中的应用
JP2015096499A (ja) 医薬組成物

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period